Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic

BACKGROUND: Fingolimod (Gilenya®) is approved for relapsing forms of multiple sclerosis in the USA. Owing to transient heart-rate effects when initiating fingolimod, eligible patients undergo precautionary baseline assessment and first-dose observation (FDO) for ≥6 h. Prior to 2014, FDO was undertak...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Brandon, Weiss, Jamie L., Kolodny, Scott, Meng, Xiangyi, Williams, Ian M., Osborne, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857316/
https://www.ncbi.nlm.nih.gov/pubmed/31729968
http://dx.doi.org/10.1186/s12883-019-1506-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857316/
https://www.ncbi.nlm.nih.gov/pubmed/31729968
http://dx.doi.org/10.1186/s12883-019-1506-0

Ejemplares similares